X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 (-) 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2018 May 16, 2018 argenx to Present at Upcoming Investor Conferences May 8, 2018 argenx reports first quarter 2018 financial results and provides business update May 7, 2018 argenx announces results of Annual General Meeting of Shareholders April 23, 2018 argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting April 11, 2018 argenx to receive third preclinical milestone payment from collaboration with LEO Pharma April 8, 2018 argenx appoints Keith Woods as Chief Operating Officer April 2, 2018 argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting March 25, 2018 argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe March 25, 2018 argenx announces Annual General Meeting of Shareholders on May 8, 2018 March 21, 2018 argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases March 15, 2018 argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies March 5, 2018 argenx to Present at Cowen & Company 38th Annual Health Care Conference Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Next page Next › Last page Last »